Bevacizumab Shows Potential as First-Line Retinopathy of Prematurity Treatment
While researchers call study results “encouraging,” they note that very low doses may be linked with reactivation.
Bill Kekevian
Bill Kekevian is the medical editor of Ophthalmology Advisor. He has served as a writer and editor covering ophthalmology and optometry for 9 years. He can be reached at [email protected]
